59 active trials 32 recruiting 21 Phase 3 22 disease areas 16 changes in 30 days
| Phase 1 | 16 | |
| Phase 1/2 | 9 | |
| Phase 2 | 6 | |
| Phase 2/3 | 2 | |
| Phase 3 | 19 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in… | Non-small Cell Lung Cancer | Recruiting | 2026-09-15 |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic… | Gastric Cancer | Recruiting | 2026-08-10 |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With… | Small Cell Lung Cancer | Recruiting | 2026-08-06 |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic… | Esophageal Squamous Cell Carcinoma | Recruiting | 2026-08-04 |
| NCT07022483 | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing… | Endometrial Cancer | Recruiting | 2026-07-28 |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for… | Ovarian Cancer | Recruiting | 2026-07-02 |
| NCT05950945 | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone… | Breast Cancer | Recruiting | 2026-06-12 |
| NCT06174987 | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | Advanced Cancer | Recruiting | 2025-10-15 |
| NCT07474649 | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without… | Coronary Atherosclerosis | Not Yet Recruiting | 2026-09-29 |
| NCT05215340 | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment… | Metastatic Non Small Cell Lung Cancer | Active, Not Recruiting | 2026-09-24 |
| NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance… | Fallopian Tube Cancer | Not Yet Recruiting | 2026-09-01 |
| NCT05338970 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in… | Nonsquamous Non-small Cell Lung Cancer | Active, Not Recruiting | 2026-08-27 |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small… | Non-small Cell Lung Cancer | Active, Not Recruiting | 2026-08-26 |
| NCT07683754 | T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line… | Advanced Breast Cancer | Not Yet Recruiting | 2026-07-23 |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD… | Leukemia | Active, Not Recruiting | 2026-07-02 |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy… | Metastatic Non Small Cell Lung Cancer | Active, Not Recruiting | 2026-06-23 |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or… | Gastric Cancer, Adenocarcinoma | Active, Not Recruiting | 2026-05-27 |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in… | HER2-Positive Primary Breast Cancer | Active, Not Recruiting | 2026-05-15 |
| NCT03529110 | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive… | Breast Cancer | Active, Not Recruiting | 2025-10-21 |
| Phase 2/3 | ||||
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus… | Urothelial Cancer | Recruiting | 2026-08-20 |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade… | Solid Cancer | Recruiting | 2026-07-28 |
| Phase 2 | ||||
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | Recruiting | 2026-10-01 |
| NCT06824168 | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid… | Acute Myeloid Leukemia | Recruiting | 2026-09-16 |
| NCT06660654 | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors… | Advanced Solid Tumor | Active, Not Recruiting | 2026-09-24 |
| NCT04619004 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced… | Non-Small Cell Lung Cancer Metastatic | Active, Not Recruiting | 2026-09-01 |
Lung Cancer (16) · Non-Small Cell Lung Cancer (NSCLC) (14) · Breast Cancer (9) · Gastric Cancer (4) · HER2-Positive Cancer (4) · Leukemia (4) · Ovarian Cancer (3) · Prostate Cancer (3) · Small Cell Lung Cancer (3) · Acute Myeloid Leukemia (AML) (2)